MARINA DEL REY, Calif., Oct. 27 /PRNewswire/ — Prostate
Oncology Specialists, Inc. of Marina del Rey is among the first
sites in the nation to treat advanced prostate cancer patients with
PROVENGE® (sipuleucel-T), the first in a new therapeutic class
known as autologous cellular immunotherapies. PROVENGE was
approved by the U.S. Food and Drug Administration (FDA) for the
treatment of men with asymptomatic or minimally symptomatic
metastatic castrate resistant (hormone refractory) prostate cancer
and is made by Dendreon Corporation.
(Photo: http://photos.prnewswire.com/prnh/20101027/SF89964)
(Photo: http://www.newscom.com/cgi-bin/prnh/20101027/SF89964)
“PROVENGE is a scientific breakthrough that paves the way for
similar personalized treatments in other cancer types,” said Dr.
Mark Scholz, Medical Director of Prostate Oncology Specialists and
co-founder of the Prostate Cancer Research Institute. “I’m pleased
to have a new option to present to my patients and to be a part of
the first physician-based facility in the area treating patients
with this important new FDA approved therapy.”
Prostate Oncology Specialists have treated over 30 patients with
PROVENGE to date, and anticipates providing the therapy to many
more men with metastatic castrate resistant prostate cancer as
supply of the drug increases over the next six months.
“I was excited about using PROVENGE because it allowed me to use
my own cells to help fight cancer,” said PROVENGE patient Frank La
Barba of Long Beach, CA. “My side-effects were mild and following
my treatment, I was able to get back to doing the activities I did
before receiving therapy, such as traveling and photography.”
PROVENGE is an autologous (made from a patient’s own immune
cells) cellular immunotherapy designed to stimulate a
patient’s
‘/>”/>
SOURCE
